Equities

Eyenovia Inc

EYEN:NAQ

Eyenovia Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.01
  • Today's Change0.073 / 7.74%
  • Shares traded2.48m
  • 1 Year change-82.43%
  • Beta1.7416
Data delayed at least 15 minutes, as of May 03 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Eyenovia, Inc. is a commercial-stage ophthalmic pharmaceutical technology company developing a pipeline of microdose array print therapeutics based on its Optejet platform. It is focused on the commercialization of Mydcombi (tropicamide+phenylephrine ophthalmic spray) for mydriasis, as well as clobetasol propionate ophthalmic suspension 0.05% to reduce pain and inflammation following ocular surgery. Its product line includes Mydcombi, clobetasol propionate, and therapeutic programs, MicroPine and MicroLine. Mydcombi is its fixed combination formulation of tropicamide-phenylephrine for inducing mydriasis for diagnostic procedures and in conditions where short-term pupil dilation is desired. MicroPine is its topical therapy for the treatment of progressive myopia, a disease associated with pathologic axial elongation of the eye and sclero-retinal stretching. MicroLine is its investigational pharmacologic treatment for presbyopia, a non-preventable, age-related hardening of the lens.

  • Revenue in USD (TTM)3.79k
  • Net income in USD-27.26m
  • Incorporated2014
  • Employees57.00
  • Location
    Eyenovia Inc295 Madison Ave Ste 2400NEW YORK 10017United StatesUSA
  • Phone+1 (813) 766-9539
  • Fax+1 (302) 636-5454
  • Websitehttps://eyenovia.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Immuneering Corp0.00-53.47m48.63m68.00--0.530-----1.89-1.890.003.090.00----0.00-47.54---51.16--------------0.00---100.00---5.86------
Ocuphire Pharma Inc19.05m-9.99m49.38m14.00--0.9561--2.59-0.4735-0.47350.87272.080.3701--5.301,360,643.00-19.40-58.31-20.77-65.94-----52.42-137.92---8.460.00---52.20---155.83------
Modular Medical Inc0.00-16.76m49.89m37.00--8.92-----0.9653-0.96530.000.18050.00----0.00-224.40-168.16-262.22-209.51------------0.00------25.51--154.53--
Odonate Inc0.00-102.07m50.02m137.00--1,844.41-----13.59-13.590.009.270.00----0.00-66.98-58.36-83.00-65.14------------0.00-------12.99------
Correlate Energy Corp7.56m-12.79m50.15m19.00------6.63-0.3554-0.35540.21-0.08772.22--13.19398,051.60-375.16-315.47----18.2715.42-169.09-201.03---0.72398.30--122.2046.12-78.54------
Hcw Biologics Inc2.84m-24.99m50.31m45.00--3.56--17.70-0.6953-0.69530.07910.37370.0755--2.9163,150.89-66.37---78.58--19.72---879.53-----90.860.319---57.72---67.74------
Ocean Biomedical Holdings Inc0.00-45.58m50.93m9.00---------1.40-1.400.00-0.0642------0.00-----------------------------612.50------
Journey Medical Corp79.18m-3.85m51.41m58.00--3.50--0.6493-0.3502-0.35024.191.050.87012.193.651,365,190.00-4.23---10.51--66.33---4.87--1.100.68630.4641--7.48--87.00------
Eyenovia Inc3.79k-27.26m51.47m57.00--5.11--13,579.80-0.6639-0.66390.000090.19760.0001--0.003166.49-91.15-80.31-119.11-117.700.00---719,290.30-680.952.16-15.140.6135------2.68--152.20--
Aadi Bioscience Inc24.35m-65.77m52.05m74.00--0.4948--2.14-2.44-2.440.90494.280.15380.67796.63273,640.40-41.54-50.25-48.46-56.1588.47---270.04-473.974.48--0.00--60.063.85-8.68--153.54--
Intensity Therapeutics Inc0.00-11.86m52.92m5.00--4.02-----0.8653-0.86530.000.96010.00----0.00-110.62---254.70--------------0.00-------56.45------
Enzo Biochem Inc32.80m-23.31m53.27m179.00--0.7419--1.62-0.46990.67080.65861.400.37381.614.10183,257.00-26.56-12.21-39.50-15.7942.1737.09-71.07-18.762.89--0.0476---4.85-21.01-23.02--7.89--
Gain Therapeutics Inc55.18k-22.27m53.43m29.00--3.81--968.36-1.74-1.740.00420.77610.0026--0.25441,902.76-104.28---132.41-------40,354.33-13,827.07----0.0432---60.6221.77-26.59--13.96--
Data as of May 03 2024. Currency figures normalised to Eyenovia Inc's reporting currency: US Dollar USD

Institutional shareholders

22.14%Per cent of shares held by top holders
HolderShares% Held
Armistice Capital LLCas of 31 Dec 20234.38m9.24%
BlackRock Fund Advisorsas of 31 Dec 20231.52m3.21%
The Vanguard Group, Inc.as of 31 Dec 20231.37m2.90%
Cowen & Co. LLCas of 31 Mar 2024827.85k1.75%
Geode Capital Management LLCas of 31 Dec 2023639.07k1.35%
Avenue Capital Management II LPas of 31 Dec 2023547.81k1.16%
SSgA Funds Management, Inc.as of 31 Dec 2023488.18k1.03%
Northern Trust Investments, Inc.(Investment Management)as of 31 Dec 2023253.25k0.53%
Renaissance Technologies LLCas of 31 Dec 2023243.88k0.52%
BNP Paribas Financial Marketsas of 31 Mar 2024219.61k0.46%
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.